SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2010 / Cilt: 20 - Sayı: 2

Transplantasyon ilişkili trombotik mikroanjiopati tanı kriterleri ve tedavi seçeneklerinin iki olgu nedeniyle gözden geçirilmesi

The overview of diagnostic criteria and treatment options of transplantation associated thrombotic microangiopathy with two case reports

Fatih ERBEY
İBRAHİM BAYRAM
Sema YILMAZ
Atila TANYELİ
Pages
110–114
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore we want to present two patients aged 5 years and 13 years who developed transplantation associated thrombotic microangiopathy after allogenic peripheric stem cell transplantation and to discuss both diagnostic criteria and treatment options of transplantation associated thrombotic microangiopathy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Transplantation associated thrombotic microangiopathy has been considered to be a severe complication of hematopoietic stem cell transplantation.
📊
Key Findings & Data:Although there has been an agreement in terms of transplantation associated thrombotic microangiopathy criteria, treatment options has not been clarified yet.
💡
Conclusion & Impact:Therefore we want to present two patients aged 5 years and 13 years who developed transplantation associated thrombotic microangiopathy after allogenic peripheric stem cell transplantation and to discuss both diagnostic criteria and treatment options of transplantation associated thrombotic microangiopathy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Transplantation associated thrombotic microangiopathy has been considered to be a severe complication of hematopoietic stem cell transplantation. Although there has been an agreement in terms of transplantation associated thrombotic microangiopathy criteria, treatment options has not been clarified yet. Therefore we want to present two patients aged 5 years and 13 years who developed transplantation associated thrombotic microangiopathy after allogenic peripheric stem cell transplantation and to discuss both diagnostic criteria and treatment options of transplantation associated thrombotic microangiopathy.

Özet

Transplantasyon ilişkili trombotik mikroanjiopati, hematopoetik kök hücre naklinin en ciddi komplikasyonlarındandır. Tanı kriterleri açısından fikir birliğine varılmış olmasına rağmen tedavi konusunda henüz bir uzlaşı bulunmamaktadır. Bu nedenle biz burada, hematopoetik kök hücre nakli sonrası transplantasyon ilişkili trombotik mikrianjiopati gelişen 5 ve 13 yaşındaki hastalarımızı sunarak, transplantasyon ilişkili trombotik mikroanjiopati tanı kriterleri ve tedavi seçeneklerini gözden geçirmek istedik.

🔖

Cite This Article

ERBEY, F., BAYRAM, İ., YILMAZ, S., TANYELİ, A. (2010). Transplantasyon ilişkili trombotik mikroanjiopati tanı kriterleri ve tedavi seçeneklerinin iki olgu nedeniyle gözden geçirilmesi. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 20 - Sayı: 2, 110–114. https://ajindex.com/articles/322934

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Powles RL, Clink HM, Spence D, et al. Cyclosporine A to prevent graft-versus-host disease in man after allogeneic bone marrow transplantation. Lancet 1: 327-329, 1980
  2. Ruutu T, Giovanni B, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 92: 95-100, 2007
  3. ED Batts, HM Lazarus. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 40: 709-719, 2007
  4. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe venoocclusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 92: 737-744, 1998
  5. Corti P, Uderzo C, Tagliabue A, et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant 29: 542-543, 2002
  6. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 100: 4337-4343, 2002
  7. Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 33: 189-195, 2004
  8. Schroder H. Defibrotide protects endothelial cells, but not L929 tumor cells, from tumor necrosis factor-amediated cytotoxicity. J Pharm Pharmocol 47: 250-252, 1995
  9. Wolff D, Wilhelm S, Hahn J, et al. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Bone Marrow Transplant 38: 445-451, 2006
  10. Au WY, Ma ES, Lee TL, et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 137: 475-478, 2007
  11. Takatsuka H, Takemoto Y, Iwata N, et al. Oral eicosapentoenoic acid for complications of bone marrow transplantation. Bone Marrow Transplant 28: 769-774, 2001
  12. Kajiume T, Nagita A, Yoshimi S, et al. A case of hemolytic-uremic syndrome improved with nitric oxide. Bone Marrow Tr